UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or other juris ...

EMERYVILLE, Calif., Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT.The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.c ...

libre de droit Facts are threatening to those invested in fraud.”― DaShanne Stokes. Today, we put Dynavax Technologies Corporation (NASDAQ:DVAX) in the spotlight as 2024 commences. This is a name that has been a rock-solid covered call holding within my portfolio for several years. The company got a burst a revenue from the Covid pandemic, which has now all but completely dissipated. However, this bounty helped the company bolster its cash reserves, establish itself as the standard of care in the hepati ...

Forward-Looking Statements © Copyright DYNAVAX 2023 2 | Q3 2023 Business Highlights Ryan Spencer Chief Executive Officer Clinical Pipeline Update Robert Janssen Chief Medical Officer Q&A Session Dynavax Core Strategic Priorities • Increase market share to become the market leader by 2027 • Deliver on our innovative and diversified pipeline leveraging CpG 1018® adjuvant with proven antigens | --- | --- | |--------------------|-------| | | | | | | | Identify Strategic | | | Opportunities to | | | Accelerate G ...

Start Time: 16:30 January 1, 0000 4:59 PM ET Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2023 Earnings Conference Call November 02, 2023, 16:30 PM ET Company Participants Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Paul Cox - VP of IR and Corporate Communications Conference Call Participants Matthew Phipps - William Blair Ernesto Rodriguez-Dumont - TD Cowen Jonathan Miller - Evercore ISI Roy Buchanan - JMP Securities Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State ...

Financial Data and Key Metrics Changes - Dynavax reported total revenues of $60 million for Q2 2023, with HEPLISAV-B net product revenue of $56 million, reflecting a 73% year-over-year growth [44][35] - The company raised its full-year revenue expectations for HEPLISAV-B to a range of $200 million to $250 million, up from the previous range of $165 million to $185 million, indicating a projected growth of 58% to 70% year-over-year [32][44] - Gross margins for HEPLISAV-B improved to approximately 76% in Q2 2023, compared to about 69% in the same period last year [20][44] Business Line Data and Key Metrics Changes - HEPLISAV-B's market share increased to approximately 39% in the overall hepatitis B vaccine market, up from 32% a year ago [9] - In the Integrated Delivery Networks (IDN) segment, HEPLISAV-B's market share rose to approximately 53%, compared to 39% at the end of Q2 2022 [10] - Dose volume for HEPLISAV-B in the retail pharmacy segment increased by 78% year-over-year, although market share remained consistent at 45% [36][37] Market Data and Key Metrics Changes - The hepatitis B vaccine market in the U.S. is estimated to grow to over $800 million by 2027, driven by the ACIP's universal recommendation for hepatitis B vaccination [34] - The overall hepatitis B vaccine market grew approximately 40% year-over-year in Q2 2023 [9] Company Strategy and Development Direction - The company is focusing on external opportunities in commercial or late-stage assets in the vaccine space and high-synergy commercial assets within the infectious disease space [33] - Dynavax aims to optimize its sales force to expand promotional reach in the retail pharmacy and IDN segments, which are expected to represent approximately 60% of the hepatitis B market by 2027 [12][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in HEPLISAV-B's market leadership and the continued expansion of the hepatitis B vaccine market, driven by strong commercial execution [13][39] - The company anticipates positive free cash flow for 2023 and believes its current capital is sufficient to support core business growth without needing to return to capital markets [21][54] Other Important Information - The company is advancing its clinical pipeline, including three vaccine candidates for Tdap, Shingles, and Plague, with plans for a Phase 1/2 trial initiation in early 2024 [16][41] - Dynavax established a Scientific Advisory Board to support its vaccine research and development efforts [18] Q&A Session Summary Question: Market growth expectations for hepatitis B - Management noted that market growth is accelerating faster than previously forecasted, particularly in retail and IDN segments [56] Question: HEPLISAV gross margins outlook - Management indicated that gross margins are expected to remain in the mid to high 70s for the year, reflecting improvements from manufacturing investments [61] Question: Tdap nonhuman challenge study details - Management confirmed that the Tdap challenge study is part of a longer-term development plan and will help establish a model for testing efficacy in humans [77][87] Question: Commercial optimization strategies - Management discussed optimizing the sales force to engage at various levels within retail chains to drive recommendations for hepatitis B vaccination [92]

| --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------|-------|-------|-----------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Second Quarter 2023 Financial Results | | | | | | | | | | | | Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases | | | | | | | | | August 3, 2023 Nasdaq: DVAX | | Statements contained in this presentation regard ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or ot ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Paul Cox - VP of IR and Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Joshua Schimmer - Evercore ISI Roy Buchanan - JMP Securities Ed White - H.C. Wainwright Ernie Rodriguez - TD Cowen Operator Good day ladies and gentlemen. And welc ...